Literature DB >> 22930722

Activation of the alternative complement pathway in vitreous is controlled by genetics in age-related macular degeneration.

Kelly M Loyet1, Laura E Deforge, Kenneth J Katschke, Lauri Diehl, Robert R Graham, Lily Pao, Lizette Sturgeon, Sock-Cheng Lewin-Koh, Joe G Hollyfield, Menno van Lookeren Campagne.   

Abstract

PURPOSE: To determine if the progression of age-related macular degeneration (AMD) is associated with complement activation in the eye.
METHODS: Immunohistochemistry and ELISAs were used to determine the distribution, concentration, and activation of the alternative pathway complement proteases factor B (FB) and factor D (FD) and the central complement protein C3 in genotyped human postmortem donor eyes graded as having no or minimal drusen (category 1; controls), large drusen (category 3), and large drusen with advanced AMD (category 4).
RESULTS: C3, FB, and FD were present in vitreous and Bruch's membrane choroid (BM/C) interface of the macula of eyes in all tested AMD severity categories (n = 100). C3, FB, and FD were predominantly located to the choroidal vasculature and Bruch's membrane and, together with the serum proteins transferrin and albumin, elevated in BM/C extracts of category 4 eyes (n = 23) compared with category 1 eyes (n = 24). A significant increase in FB activation was found only in vitreous of category 4 eyes (n = 23) compared with category 1 eyes (n = 25). Genetic variants of complement factor H (CFH), C3, C2, and FB associated with increased risk of AMD were correlated with alternative pathway complement activation in vitreous, but not with complement proteins in BM/C protein extracts.
CONCLUSIONS: Increased activation of the alternative complement pathway in vitreous was controlled by disease stage and genetic variation in the complement pathway, supporting a role for complement activation in AMD disease pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22930722     DOI: 10.1167/iovs.12-9587

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  24 in total

1.  Early local activation of complement in aqueous humour of patients with age-related macular degeneration.

Authors:  L Altay; V Sitnilska; T Schick; G Widmer; G Duchateau-Nguyen; P Piraino; A Jayagopal; F M Drawnel; S Fauser
Journal:  Eye (Lond)       Date:  2019-07-02       Impact factor: 3.775

2.  Increased serum proteins in non-exudative AMD retinas.

Authors:  Hannah Schultz; Ying Song; Bailey H Baumann; Rebecca J Kapphahn; Sandra R Montezuma; Deborah A Ferrington; Joshua L Dunaief
Journal:  Exp Eye Res       Date:  2019-05-31       Impact factor: 3.467

Review 3.  Recent developments in the treatment of age-related macular degeneration.

Authors:  Frank G Holz; Steffen Schmitz-Valckenberg; Monika Fleckenstein
Journal:  J Clin Invest       Date:  2014-04-01       Impact factor: 14.808

4.  Inhibitors of factor d may provide a treatment for age-related macular degeneration.

Authors:  Ahmed F Abdel-Magid
Journal:  ACS Med Chem Lett       Date:  2014-01-30       Impact factor: 4.345

Review 5.  Complement factor H in AMD: Bridging genetic associations and pathobiology.

Authors:  Christopher B Toomey; Lincoln V Johnson; Catherine Bowes Rickman
Journal:  Prog Retin Eye Res       Date:  2017-09-18       Impact factor: 21.198

6.  As in Real Estate, Location Matters: Cellular Expression of Complement Varies Between Macular and Peripheral Regions of the Retina and Supporting Tissues.

Authors:  Randy Zauhar; Josef Biber; Yassin Jabri; Mijin Kim; Jian Hu; Lew Kaplan; Anna M Pfaller; Nicole Schäfer; Volker Enzmann; Ursula Schlötzer-Schrehardt; Tobias Straub; Stefanie M Hauck; Paul D Gamlin; Michael B McFerrin; Jeffrey Messinger; Christianne E Strang; Christine A Curcio; Nicholas Dana; Diana Pauly; Antje Grosche; Mingyao Li; Dwight Stambolian
Journal:  Front Immunol       Date:  2022-06-15       Impact factor: 8.786

7.  The effect of systemic levels of TNF-alpha and complement pathway activity on outcomes of VEGF inhibition in neovascular AMD.

Authors:  Adnan H Khan; Charles O Pierce; Gabriella De Salvo; Helen Griffiths; Marie Nelson; Angela J Cree; Geeta Menon; Andrew J Lotery
Journal:  Eye (Lond)       Date:  2021-11-08       Impact factor: 4.456

Review 8.  Autophagy in the eye: implications for ocular cell health.

Authors:  Laura S Frost; Claire H Mitchell; Kathleen Boesze-Battaglia
Journal:  Exp Eye Res       Date:  2014-05-06       Impact factor: 3.467

9.  Prolonged intraocular residence and retinal tissue distribution of a fourth-generation compstatin-based C3 inhibitor in non-human primates.

Authors:  Sarah Hughes; Justin Gumas; Rebecca Lee; Merita Rumano; Nadja Berger; Avneesh Kumar Gautam; Georgia Sfyroera; Anna Lorena Chan; Gopalan Gnanaguru; Kip M Connor; Benjamin J Kim; Joshua L Dunaief; Daniel Ricklin; George Hajishengallis; Despina Yancopoulou; Edimara S Reis; Dimitrios C Mastellos; John D Lambris
Journal:  Clin Immunol       Date:  2020-03-27       Impact factor: 3.969

10.  Systemic complement activation levels in Stargardt disease.

Authors:  Patty P A Dhooge; Esmee H Runhart; Catherina H Z Li; Corrie M de Kat Angelino; Carel B Hoyng; Renate G van der Molen; Anneke I den Hollander
Journal:  PLoS One       Date:  2021-06-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.